By affecting the palmitoylation of GNA13, these cancer cells with a wild-type GNA13 protein became again sensitized to a BCL2 inhibitor, suggesting GNA13 palmitoylation as potential target for combinatory therapy with BCL2 inhibitors (53). Here, BCL2 is linked to cancer.